OnKure Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
Mailing Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
Phone
(720) 307-2892
Fiscal Year End
1231
EIN
472309515
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 7, 2026 | View on SEC |
| SCHEDULE 13D Beneficial ownership report (>5%) | April 7, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 7, 2026 | View on SEC |
| 3 Initial insider ownership report | April 7, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 7, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| 4 Insider stock transaction report | April 3, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | April 1, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Clinical-stage biotech focused on developing new cancer treatments for unmet medical needs.
- Lead drug candidate, OKI-219, is currently in Phase 2 clinical trials.
Insider Trading
SELL
2 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.